Logotype for Intellia Therapeutics Inc

Intellia Therapeutics (NTLA) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Intellia Therapeutics Inc

Q3 2026 earnings summary

5 Nov, 2026

Executive summary

  • FDA accepted the lonvo-z BLA for Priority Review, set a March 10, 2027 PDUFA date and is not currently planning an advisory committee meeting.

  • HAELO Phase 3 met its primary and key secondary endpoints: attacks fell 87% vs. placebo, 62% were attack-free and therapy-free vs. 11%, and no serious adverse events occurred in the lonvo-z arm.

  • Nex-z Phase 3 studies resumed after FDA holds were lifted; MAGNITUDE-2 enrollment was completed, and MAGNITUDE enrollment continued.

  • Q1 2027 U.S. launch preparation advanced, including deployment of a field organization and engagement with HAE centers and payers, subject to approval.

Financial highlights

  • Q3 collaboration revenue was $7.2M vs. $13.8M, primarily reflecting lower Regeneron revenue; 9M revenue was $29.9M vs. $44.7M, also affected by lower material shipments and a 2025 hemophilia B milestone.

  • Q3 R&D expense was $83.3M vs. $94.7M; lower lonvo-z external costs, stock-based compensation and research costs were partly offset by higher headcount expense.

  • Q3 G&A rose to $46.1M from $30.5M, driven by commercial infrastructure, legal, facility and compensation costs; 9M G&A rose $32.1M to $118.8M.

  • Q3 operating expenses were $129.5M vs. $125.3M; operating loss was $122.3M vs. $111.5M and net loss was $127.5M vs. $101.3M.

  • 9M operating expenses fell to $365.5M from $386.9M and operating loss narrowed to $335.6M from $342.3M, while net loss widened to $330.4M from $316.9M.

Outlook and guidance

  • Cash, cash equivalents and marketable securities of $614.8M at Sept. 30, 2026 are expected to fund operating expenses and capital needs at least into 2028; guidance excludes potential lonvo-z revenue, milestone payments and strategic uses.

  • 2026 R&D expense is expected to decrease as resources focus on lonvo-z and nex-z, mostly offset by commercial infrastructure spending.

  • Planned lonvo-z U.S. launch is in Q1 2027, subject to FDA approval; readiness work is on track ahead of the PDUFA date.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Intellia Therapeutics